Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Salman Otoukesh, MD, Hany Elmariah, MDMS, Dongyun Yang, PhD, Sally Mokhtari, PhD, Madiha Siraj, Haris Ali, MD, Krishnakar Mogili, Shukaib Arslan, MD, Taiga Nishihori, MD, Chatchada Karanes, MD, Joseph Pidala, MD, Ryotaro Nakamura, MD, Claudio Anasetti, MD, Stephen J. Forman, MD, Monzr M. Al Malki, MD, Nelli Bejanyan, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-143166

Published: 2020

Journal Articles

No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial

Filippo Milano, MD PhD, Andrew R Rezvani, MD, Joanne Kurtzberg, MD, Chatchada Karanes, MD, Jonathan A Gutman, MD, Christine Duncan, MD, Alla Keyzner, MD, Rabi Hanna, MD, Tonya Kimberly Marmon, PhD, Ann Dahlberg, MD, Colleen Delaney, MD MSc

Blood (2019) 134 (Supplement_1): 146.

https://doi.org/10.1182/blood-2019-130716

Published: 2019

Journal Articles

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Blood (2019) 134 (Supplement_1): 4394.

https://doi.org/10.1182/blood-2019-126080

Published: 2019

Journal Articles

Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions

Aaron D Goldberg, MD PhD, Catherine C. Coombs, MD, Eunice S. Wang, MD, Roland B. Walter, MD PhD MS, Chatchada Karanes, MD, Carlos Enrique Vigil, MD, Boo Messahel, MD, Richard M. Stone, MD, Robert H. Collins, MD

Blood (2019) 134 (Supplement_1): 1326.

https://doi.org/10.1182/blood-2019-130863

Published: 2019

Journal Articles

Low Relapse Rate in Younger Patients ≤ 60 Years Old with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) Treated with Crenolanib and Cytarabine/Anthracycline Chemotherapy

Eunice S. Wang, MD, Martin S. Tallman, MD, Richard M. Stone, MD, Roland B. Walter, MD PhD, Chatchada Karanes, MD, Vinay Jain, MBBS, MD, Robert H. Collins, MD

Blood (2017) 130 (Supplement 1): 566.

https://doi.org/10.1182/blood.V130.Suppl_1.566.566

Published: 2017

Journal Articles

Pro-Tmune, the Next Generation Graft for Allogeneic Hematopoietic Cell Transplantation: Phase 1 Safety and Efficacy Data

Richard Maziarz, MD, John Edwards, MD, James Essell, MD, Cesar Freytes, MD, Chatchada Karanes, MD, Ayman Saad, MD, Dimitrios Tzachanis, MD PhD, Monica Diaz, Amanda Medcalf, Daniel Fremgen, Chris Storgard, MD, Abhinav Deol, MD

Blood (2017) 130 (Supplement 1): 4498.

https://doi.org/10.1182/blood.V130.Suppl_1.4498.4498

Published: 2017

Journal Articles

A Phase II Study of Total Marrow and Lymphoid Irradiation (TMLI) in Combination with Cyclophosphamide and Etoposide in Patients with Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Blood (2017) 130 (Supplement 1): 4607.

https://doi.org/10.1182/blood.V130.Suppl_1.4607.4607

Published: 2017

Journal Articles

Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Ajai Chari, MD, Saulius Girnius, MD, Saurabh Chhabra, MD, Robert Frank Cornell, MD, Cristina J. Gasparetto, MD, Chatchada Karanes, MD, Matthew A. Lunning, DO, Jeffrey V. Matous, MD, Ruben Niesvizky, MD, Chaim Shustik, MD, Robert K. Stuart, MD, Jason Lih, PhD, Yihua Lee, PhD, Zeena Salman, Thorsten Graef, MD PhD, Jason Valent, MD

Blood (2017) 130 (Supplement 1): 3111.

https://doi.org/10.1182/blood.V130.Suppl_1.3111.3111

Published: 2017

Journal Articles

Safety Study of Salvage Chemotherapy High-Dose Ara-C/Mitoxantrone (HAM) and Type I FLT3-TKI Crenolanib in First Relapsed/Primary Refractory AML

Swaminathan P. Iyer, MD, Yogesh Jethava, MD, Chatchada Karanes, MD, John R. Eckardt, MD, Robert Collins

Blood (2016) 128 (22): 3983.

https://doi.org/10.1182/blood.V128.22.3983.3983

Published: 2016

Journal Articles

A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics

Amrita Krishnan, Prashant Kapoor, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS, Shaji Kumar, MD, Sagar Lonial, MD FACP, Myo Htut, MD, Chatchada Karanes, MD, Nitya Nathwani, MD, Michael Rosenzweig, MD, Firoozeh Sahebi, MD, George Somlo, MD FACP, Lupe Duarte, CTA, Stephen J. Forman, MD, James F Sanchez, PhD, Jesus G. Berdeja, MD

Blood (2016) 128 (22): 3316.

https://doi.org/10.1182/blood.V128.22.3316.3316

Published: 2016

Journal Articles

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Ajai Chari, MD, Saurabh Chhabra, MD, Saad Usmani, MD, Sarah Larson, MD, Ruben Niesvizky, MD, Jeffrey Matous, MD, Cristina Gasparetto, MD, Beata Holkova, MD, Matthew Lunning, DO, Jason Valent, MD, Larry D. Anderson, Jr., MD PhD, Chatchada Karanes, MD, Long Kwei, PhD, Lipo Chang, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Kevin McDonagh, MD

Blood (2015) 126 (23): 377.

https://doi.org/10.1182/blood.V126.23.377.377

Published: 2015

Journal Articles

Ex Vivo Pharmacologic Modulation in a Nutrient-Rich Medium to Accelerate Engraftment of Human Umbilical Cord Blood

Corey S Cutler, MD MPH, Daniel Shoemaker, PhD, Peter Westervelt, MD PhD, Daniel R. Couriel, MD, Sumithra Vasu, MBBS, Luis M. Isola, MD, Chatchada Karanes, MD, Laura Newell, MD, Betsy Rezner, BS, Lisa Guerrettaz, PhD, David Robbins, BS, Amanda Medcalf, BS, MT(ASCP), Scott Wolchko, MS, John Ferraro, MBA, Pratik S. Multani, MD MS

Blood (2014) 124 (21): 3807.

https://doi.org/10.1182/blood.V124.21.3807.3807

Published: 2014

Journal Articles

NK Cell Recovery and Costimulatory Molecule Profiles after Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM) Patients

Myo Htut, MD, Ghislaine Gallez-Hawkins, Joycelynne Palmer, PhD, Laetitia Jeannet, Leanne Goldstein, Andy Dagis, Ricardo Spielberger, MD, Pablo Miguel Parker, Len Farol, MD, Firoozeh Sahebi, MD, Chatchada Karanes, MD, Stephen J. Forman, Amrita Krishnan, MD, John A. Zaia, MD

Blood (2014) 124 (21): 2039.

https://doi.org/10.1182/blood.V124.21.2039.2039

Published: 2014

Journal Articles

Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT

Robert Chen, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS MPH, Sandra H. Thomas, PhD, Tanya Paris, Leslie Popplewell, MD, Chatchada Karanes, MD, Tanya Siddiqi, MD, Auayporn Nademanee, MD, Ji-Lian Cai, MD, Stephen J. Forman, MD

Blood (2013) 122 (21): 3374.

https://doi.org/10.1182/blood.V122.21.3374.3374

Published: 2013

Journal Articles

Dose Dependent Enhancement Of Neutrophil Recovery By Infusion Of Notch Ligand Ex Vivo Expanded Cord Blood Progenitors: Results Of a Multi-Center Phase I Trial

Colleen Delaney, MD, MSC, Filippo Milano, MD, PhD, Ian Nicoud, PhD, Shelly Heimfeld, PhD, Chatchada Karanes, MD, Jonathan A Gutman, MD, John E. Wagner, MD, Frederick R. Appelbaum, MD, Irwin D. Bernstein, MD

Blood (2013) 122 (21): 297.

https://doi.org/10.1182/blood.V122.21.297.297

Published: 2013

Journal Articles

Significant and Rapid Improvement in Survival After Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT): Analysis of National Marrow Donor Program (NMDP) Facilitated Transplants From 2000 to 2009

Blood (2012) 120 (21): 234.

https://doi.org/10.1182/blood.V120.21.234.234

Published: 2012

Journal Articles

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

George Somlo, MD, Paul Frankel, PhD, Ricardo Spielberger, MD, Chatchada Karanes, MD, Amrita Krishnan, MD, Pablo Parker, MD, Leslie Popplewell, MD, Firoozeh Sahebi, MD, Timothy Schultheiss, PhD, Neil Martin Kogut, MD, David S. Snyder, MD, Anthony Selwyn Stein, M.D., Stephen J. Forman, MD, Jeffrey Wong, MD

Blood (2012) 120 (21): 3151.

https://doi.org/10.1182/blood.V120.21.3151.3151

Published: 2012

Journal Articles

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma

Robert W. Chen, MD, Stephen J. Forman, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS, Leslie Popplewell, MD, Maria L Delioukina, MD, Torres Alejandra, MS, Bernadette Pulone, RN, OCN, Eileen P. Smith, MD, Auayporn P. Nademanee, MD, Chatchada Karanes, MD, Paul O'Donnell, MD, PhD, David G. Maloney, MD, PhD, Len Farol, MD, Schickwann Tsai, MD, PhD, Laurie E. Grove, PA-C, Ajay K. Gopal, MD

Blood (2011) 118 (21): 664.

https://doi.org/10.1182/blood.V118.21.664.664

Published: 2011

Journal Articles

Costimulatory Molecule Profiles After Autologous Hematopoietic Cell Transplantation (HCT) in Multiple Myeloma (MM) Patients

Myo Htut, MD, Ghislaine Gallez-Hawkins, Joycelynne Palmer, PhD, Xueli Liu, R. Spielberger, M.D., Pablo Parker, M.D., Len Farol, MD, Anne Franck, Xiuli Li, Jeannet Laëtitia, Eunicia Reburiano, Valerie Jimenez, Lupe Duarte, CCRC, Chatchada Karanes, MD, Stephen J. Forman, MD, John Zaia, MD, Amrita Krishnan, MD

Blood (2011) 118 (21): 5108.

https://doi.org/10.1182/blood.V118.21.5108.5108

Published: 2011

Journal Articles

Early Mortality After Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Performed In the Recent Era

Lester A. Laddaran, B.A., Can-Lan Sun, Ph.D., Ari M. VanderWalde, MD, MPH, Liton Francisco, B.S., Saro Armenian, D.O., M.P.H., Jennifer Berano Teh, M.D., F. Lennie Wong, Ph.D., Chatchada Karanes, MD, Neil Martin Kogut, MD, Amrita Krishnan, M.D., Auayporn Nademanee, M.D., Margaret O'Donnell, M.D., F.R.C.P.C., Pablo Parker, M.D., Leslie Popplewell, M.D., Anthony Selwyn Stein, M.D., Stephen J. Forman, M.D., Smita Bhatia

Blood (2010) 116 (21): 902.

https://doi.org/10.1182/blood.V116.21.902.902

Published: 2010

NARROW

Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions

Low Relapse Rate in Younger Patients ≤ 60 Years Old with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) Treated with Crenolanib and Cytarabine/Anthracycline Chemotherapy

Pro-Tmune, the Next Generation Graft for Allogeneic Hematopoietic Cell Transplantation: Phase 1 Safety and Efficacy Data

A Phase II Study of Total Marrow and Lymphoid Irradiation (TMLI) in Combination with Cyclophosphamide and Etoposide in Patients with Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Safety Study of Salvage Chemotherapy High-Dose Ara-C/Mitoxantrone (HAM) and Type I FLT3-TKI Crenolanib in First Relapsed/Primary Refractory AML

A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Ex Vivo Pharmacologic Modulation in a Nutrient-Rich Medium to Accelerate Engraftment of Human Umbilical Cord Blood

NK Cell Recovery and Costimulatory Molecule Profiles after Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM) Patients

Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT

Dose Dependent Enhancement Of Neutrophil Recovery By Infusion Of Notch Ligand Ex Vivo Expanded Cord Blood Progenitors: Results Of a Multi-Center Phase I Trial

Significant and Rapid Improvement in Survival After Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT): Analysis of National Marrow Donor Program (NMDP) Facilitated Transplants From 2000 to 2009

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma

Costimulatory Molecule Profiles After Autologous Hematopoietic Cell Transplantation (HCT) in Multiple Myeloma (MM) Patients

Early Mortality After Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Performed In the Recent Era

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only